GILD · Gilead Sciences
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $154
Note written ·
Price against the kill line
10.6% clear of its kill line on the 17 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 17 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $154.00, set on 14 November 2026. The shares are up 16.0% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $154, under the 50-day moving average, which would show the gain since the results unwinding. An FDA complete response letter for anito-cel by 23 December 2026 would also break the case.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Gilead Sciences develops and sells prescription medicines. Most sales come from HIV treatment and prevention drugs such as Biktarvy, Descovy and Yeztugo; the rest come from liver-disease, cancer and cell therapies. It sells mainly through US drug wholesalers and is paid by insurers and government programs. Revenue was $8,300 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 29 October 2026 Gilead raised its 2026 product sales guidance to $31,000–31,300 million, from $30,100–30,400 million, after HIV sales rose 18% to $6,249 million in the third quarter.
- What follows for the company
- Gross margin reached 81.1% in the third quarter. About $12.4 billion of 2026 acquisition charges turned full-year earnings into a loss. Cash fell to $6,437 million against $26,231 million of debt.
- What follows for its customers, suppliers and competitors
- Prevention growth competes with GSK (GSK) and Merck (MRK) in HIV. Anito-cel would take on Johnson & Johnson (JNJ), Legend Biotech (LEGN) and Bristol Myers Squibb (BMY) in myeloma.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 30 October 2026), the shares trade at an EV/sales of 7.4, a P/B of 16.0 and a free-cash-flow yield of 6.6%, for an enterprise value of $228,270 million. P/E and EV/EBIT are not meaningful. Those multiples hold only if revenue keeps growing near the 6.8% of the latest filed quarter and free cash flow stays near $13,780 million a year.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 30 October 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 8,300
- Revenue, change on a year (%)
- +6.8
- Gross margin (%)
- 81.1
- Operating margin (%)
- 41.7
- Free cash flow, four quarters ($M)
- 13,780
- Net cash, cash less debt ($M)
- −19,794
- Enterprise value to sales (×)
- 7.5
- Free-cash-flow yield (%)
- 6.5
All filed numbers
What Gilead Sciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 8,300 | +6.8 | 81.1 | 41.7 |
| first filed | 7,803 | +10.2 | 79.8 | −133.2 |
| first filed | 6,960 | +4.4 | 79.2 | 37.2 |
| first filed | 7,925 | +4.7 | 79.5 | 25.0 |
| first filed | 7,769 | +3.0 | 79.8 | 42.8 |
| first filed | 7,082 | +1.8 | 78.8 | 34.9 |
| Pre-tax income ($M) | 3,063 |
| Net income ($M) four quarters: −3,863 | 2,429 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −0.2 |
| Operating cash flow ($M) | 14,479 |
| Capital spending ($M) | 699 |
| Free cash flow ($M) | 13,780 |
| Cash and short-term investments ($M) | 6,437 |
| Debt ($M) non-current long-term debt plus current debt | 26,231 |
| Net cash, cash less debt ($M) | −19,794 |
| Deferred revenue ($M) +1.8% on a year | 57.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 5,007 |
| Inventory ($M) | 1,896 |
| Shareholders' equity ($M) | 13,040 |
| Market value ($M) | 211,180 |
| Enterprise value, market value plus net debt ($M) | 230,974 |
| Enterprise value to sales (×) | 7.5 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 16.2 |
| Free-cash-flow yield (%) | 6.5 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 1.7% of shares outstanding sold short, 3.2 days of average trading to cover, +4.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Customers:
- MCK, COR, CAH
The thesis
Gilead Sciences shares are rated Medium, meaning modestly more likely than not to beat the S&P 500 over the next three months. HIV sales rose 18% in the third quarter of 2026, and the company raised its 2026 sales guidance for the third time that year. The next tests are the FDA decision on the myeloma cell therapy anitocabtagene autoleucel (anito-cel), due 23 December 2026, and the fourth-quarter report expected in early February 2027.
On 29 October 2026 Gilead reported third-quarter revenue of $8,300 million, up 7% from a year earlier. Product sales excluding Veklury, its COVID-19 antiviral, rose 16% to $8,203 million. Full-year product sales guidance went to $31,000–31,300 million, up from $30,100–30,400 million. Brokers raised their targets after the report: DZ Bank to $191 on 4 November 2026, Maxim Group to $200 on 5 November 2026, Daiwa Securities to $174 on 9 November 2026 and Argus Research to $190 on 12 November 2026.
The rating is Medium because three things work against the growth. The shares rose 21.7% in the three months to 13 November 2026. Biktarvy, Gilead's largest drug, faces a Medicare negotiated price from 1 January 2028. Senior executives have kept selling shares into the rise.
Bullish and bearish views on Gilead Sciences, Inc.
The bull case on Gilead Sciences, Inc. (GILD), in brief: HIV prevention is now a growth driver. The bear case: Biktarvy faces a Medicare price cut.
Bull case
- HIV prevention is now a growth driver. In the third quarter of 2026, Descovy sales rose 49% to $1,046 million and the twice-yearly injection Yeztugo reached $305 million, against $39 million a year earlier (company results, 29 October 2026).
- Biktarvy still grows at scale. Biktarvy sales rose 10% to $4,059 million in the third quarter of 2026, which kept total HIV sales at $6,249 million (company results, 29 October 2026).
- New trial data support the next launches. In the PURPOSE 5 trial, reported 6 November 2026, 85.6% of people stayed on twice-yearly lenacapavir and none acquired HIV. In the Phase 3 IDEAL study, reported 5 November 2026, 75.4% of patients with primary biliary cholangitis (PBC) on Livdelzi reached normal alkaline phosphatase at week 52, against 16.1% on placebo.
- Oncology adds growth. Trodelvy sales rose 42% to $506 million in the third quarter of 2026. The anito-cel application has an FDA action date of 23 December 2026, and Gilead and its cell-therapy unit Kite will make 23 presentations at the American Society of Hematology (ASH) meeting on 12 December to 15 December 2026 (company releases).
- Cash generation covers the dividend. Free cash flow was $13,780 million over the four quarters to 30 September 2026 (10-Q filed 30 October 2026). The company paid $3.1 billion in dividends and bought back $1.1 billion of shares in the first nine months of 2026.
Bear case
- Biktarvy faces a Medicare price cut. The Medicare maximum fair price for Biktarvy was set in October 2026 and takes effect on 1 January 2028 (company results, 29 October 2026). Leerink Partners estimated in January 2026 that Biktarvy's Medicare revenue could be 8% of Gilead's 2027 sales, the most exposed drug on that year's list.
- Pricing pressure from Washington is rising. On 11 November 2026, Benzinga reported near-term drug-pricing risk from Washington for Gilead, Eli Lilly, Merck and Bristol Myers Squibb.
- Cell therapy sales are falling. Cell therapy sales fell 18% to $355 million in the third quarter of 2026, and Veklury fell 69% to $86 million (company results, 29 October 2026). Anito-cel would enter a declining franchise.
- Acquisitions have weakened the balance sheet. Gilead expects about $12.4 billion of acquired in-process research and development charges in 2026, about $9.88 a share, from the Arcellx, Tubulis, Ouro Medicines and PepStar deals. Full-year diluted earnings guidance is a loss of $4.40 to $4.05 a share under standard accounting. Cash and short-term investments were $6,437 million against debt of $26,231 million at 30 September 2026 (10-Q).
- Executives sold into the rise. Chairman and CEO Daniel O'Day exercised options and sold 112,429 shares at an average of $175.16 on 4 November 2026 and 5 November 2026. He also sold 30,881 shares at an average of $172.57 from 30 October to 2 November 2026. All of these sales were made under Rule 10b5-1 trading plans (SEC Form 4 filings).
Price setup
Gilead closed at $168.08 on 13 November 2026. That is 4.8% below the 52-week intraday high of $176.58, set on 5 November 2026, and well above the 52-week closing low of $118.30 on 5 January 2026. Over the week of 9 November 2026 the shares closed between $167.95 and $170.87. They gave back part of the early-November rise but held most of the gain since the results.
On adjusted daily closes, the shares are up 21.7% over three months, from the 17 August 2026 reference close. The last close sits above the 50-day moving average of $155.0 and the 200-day moving average of $140.58. The 50-day average is the nearest level that tracks the gain since the results.
A common market view is that large drugmakers re-rate slowly after guidance raises. Across liquid US stocks, the spread of three-month returns was 27% in 2026, against 15% in 2017. Results specific to each company have driven more of the outcome than in earlier years. That makes the anito-cel decision and the fourth-quarter guidance matter more than the price trend.
Catalysts ahead
- 12 December 2026: Gilead and Kite present 23 data updates at the American Society of Hematology meeting, 12 December to 15 December 2026. The anito-cel data presented there shape expectations for a myeloma cell therapy launch that would need to reverse the 18% third-quarter decline in cell therapy sales.
- 23 December 2026: FDA action date for anito-cel in relapsed or refractory multiple myeloma. An approval adds a new oncology product to the 2027 outlook; a complete response letter would break the case that the pipeline offsets the Biktarvy Medicare price.
- ~10 February 2027 (est.): Fourth-quarter 2026 results and 2027 guidance. The 2027 outlook shows whether HIV prevention growth keeps total product sales rising ahead of the 2028 Biktarvy Medicare price.
What would change the view
A daily close below $154, under the 50-day moving average, which would show the gain since the results unwinding. An FDA complete response letter for anito-cel by 23 December 2026 would also break the case.
The risks this note tracks, each with what would confirm it:
- US drug-pricing pressure widens beyond the 2028 Biktarvy Medicare negotiated price. Confirmed by: new legislation or a Centers for Medicare & Medicaid Services action naming additional Gilead HIV drugs, or the company cutting its HIV growth outlook because of pricing.
- The Yeztugo prevention launch slows after its strong third quarter. Confirmed by: fourth-quarter 2026 Yeztugo sales below the third quarter's $305 million when the company reports in early 2027.
- The anito-cel review is delayed or rejected, which would leave the cell therapy franchise shrinking. Confirmed by: a complete response letter or an extended review instead of an FDA action on 23 December 2026.
- Acquisition spending and dividends strain a balance sheet with $26,231 million of debt. Confirmed by: further large acquisitions funded by new debt, or a pause in share repurchases, disclosed in the fourth-quarter 2026 report.
- Continued executive selling weighs on the shares after a 21.7% three-month rise. Confirmed by: further open-market sales by the CEO or CFO reported on SEC Form 4 filings as the price nears its 5 November 2026 high.
What it trades with
Gilead trades with large-cap US pharmaceutical companies on drug-pricing news. The 11 November 2026 Benzinga report grouped it with Eli Lilly (LLY), Merck (MRK) and Bristol Myers Squibb (BMY). In HIV, its main competitors are ViiV Healthcare, majority-owned by GSK (GSK), and Merck. In multiple myeloma cell therapy, anito-cel would compete with Carvykti from Johnson & Johnson (JNJ) and Legend Biotech (LEGN), and with Abecma from Bristol Myers Squibb. Trodelvy competes with AstraZeneca (AZN) in breast cancer.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $8,300 million, up 7% from a year earlier; product sales excluding Veklury rose 16% to $8,203 million. Gilead third-quarter 2026 results release · as of
- Full-year 2026 product sales guidance was raised to $31,000–31,300 million from $30,100–30,400 million. Gilead third-quarter 2026 results release · as of
- Third-quarter 2026 HIV sales were $6,249 million, up 18%; Descovy rose 49% to $1,046 million and Yeztugo reached $305 million. Gilead third-quarter 2026 results release · as of
- Cell therapy sales fell 18% to $355 million and Veklury fell 69% to $86 million in the third quarter of 2026. Gilead third-quarter 2026 results release · as of
- Free cash flow was $13,780 million over the four quarters to 30 September 2026; debt was $26,231 million against $6,437 million of cash and short-term investments. Gilead 10-Q for the quarter to 30 September 2026 · as of
- In the Phase 3 IDEAL study, 75.4% of patients with primary biliary cholangitis on Livdelzi reached normal alkaline phosphatase at week 52, against 16.1% on placebo. Gilead IDEAL study announcement · as of
- CEO Daniel O'Day sold 112,429 shares at an average of $175.16 on 4 November 2026 and 5 November 2026 after exercising options, under a Rule 10b5-1 plan. SEC Form 4 filed 6 November 2026 · as of
- Argus Research raised its Gilead price target to $190 from $165. Argus Research note reported 12 November 2026 · as of
Sources
- Share Article · gilead.com ·
- Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 · gilead.com
- Drugs for cancer, arthritis and HIV on Medicare's list for 2028 price cuts · biopharmadive.com ·